Investigation of PPAR-gamma antagonists as antiOSA drug.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25463035
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Prosthodontics/ Dental materials science and
• Research Institution: Tsurumi University
• Principal Investigator: Iida Ryohei 鶴見大学, 歯学部, 助教 (70339810)
• Co-Investigator(Kenkyū-buntansha): Ogawa Takumi 鶴見大学, 歯学部, 教授 (20267537) ; Ando Hitoshi 鶴見大学, 歯学部, 講師 (00282765)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: クレンブテロール / PPARγ / IGF-1

Outline of Final Research Achievements

The aim of this study was HX531 or clenbuterol could be the drug for obstructive sleep apnea (OSA). Growth of the minimum diameter of masseter muscle fibers was stopped within 2 weeks in rats gave an antagonist of PPARγ, clenbuterol, although that increased until 3 weeks in control. Body weight was kept increased in both of rats, This result suggests clenbuterol may have the ability as the antiOSA drug. Our next focus was the mechanism how diameter of masseter reduced by clenbuterol. We investigated miogenic factors such as MyoD, myogenin, MCK, myostatin and IGF-1. Among them, expression of IGF-1 mRNA was markedly increased in masseter of rats with clenbuterol for 2 weeks. This result indicates that IGF-1 may have a role for repressing the growth of masseter, not gastrocnemius muscle.

Free Research Field

医歯薬学